Monashee Investment Management LLC purchased a new stake in shares of Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - Free Report) in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 159,942 shares of the company's stock, valued at approximately $3,511,000. Monashee Investment Management LLC owned approximately 0.18% of Ascentage Pharma Group International at the end of the most recent quarter.
Ascentage Pharma Group International Stock Performance
Shares of AAPG stock opened at $47.20 on Thursday. The company's fifty day simple moving average is $39.53. The company has a debt-to-equity ratio of 3.24, a current ratio of 1.26 and a quick ratio of 1.26. Ascentage Pharma Group International - Unsponsored ADR has a 12 month low of $16.50 and a 12 month high of $47.78.
Ascentage Pharma Group International Company Profile
(
Free Report)
Ascentage Pharma Group International Co, Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.
Read More
Want to see what other hedge funds are holding AAPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Ascentage Pharma Group International, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascentage Pharma Group International wasn't on the list.
While Ascentage Pharma Group International currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access